Jasper Therapeutics, Inc. (NASDAQ:JSPR) Given Average Recommendation of “Hold” by Analysts

Jasper Therapeutics, Inc. (NASDAQ:JSPR) has been assigned an average recommendation of “Hold” from the eight ratings firms that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and four have issued a buy recommendation on the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $12.00.

Several research firms have commented on JSPR. Wall Street Zen upgraded shares of Jasper Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, July 25th. Royal Bank Of Canada set a $3.00 target price on Jasper Therapeutics and gave the stock a “sector perform” rating in a research note on Friday, May 15th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Jasper Therapeutics in a report on Friday, July 17th. Finally, TD Cowen downgraded Jasper Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, May 15th.

Jasper Therapeutics Price Performance

NASDAQ JSPR opened at $0.60 on Thursday. Jasper Therapeutics has a 1 year low of $0.32 and a 1 year high of $3.14. The firm has a market cap of $16.80 million, a price-to-earnings ratio of -0.19 and a beta of 3.07. The company has a fifty day moving average price of $0.60 and a 200-day moving average price of $0.97.

Jasper Therapeutics (NASDAQ:JSPR) last announced its earnings results on Thursday, May 14th. The company reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.46) by $0.08. On average, research analysts anticipate that Jasper Therapeutics will post -1.67 EPS for the current fiscal year.

Institutional Investors Weigh In On Jasper Therapeutics

Large investors have recently made changes to their positions in the business. Knott David M Jr raised its stake in shares of Jasper Therapeutics by 5.8% during the 4th quarter. Knott David M Jr now owns 181,389 shares of the company’s stock worth $332,000 after purchasing an additional 10,000 shares during the period. Acadian Asset Management LLC purchased a new position in shares of Jasper Therapeutics in the 1st quarter worth about $46,000. Engineers Gate Manager LP bought a new position in Jasper Therapeutics during the second quarter valued at about $78,000. Renaissance Technologies LLC grew its position in Jasper Therapeutics by 9.0% during the fourth quarter. Renaissance Technologies LLC now owns 227,183 shares of the company’s stock valued at $416,000 after buying an additional 18,683 shares during the period. Finally, Panagora Asset Management Inc. purchased a new stake in Jasper Therapeutics during the fourth quarter worth about $35,000. 79.85% of the stock is owned by hedge funds and other institutional investors.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine.

Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation.